Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.47 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29467983 | 0.87 | ACLY (0.52) | SLC22A12PARP14PGRACLYMAP2K1 | |
| SCHEMBL10208423 | 0.87 | ACLY (0.52) | SLC22A12PARP14PGRACLYMAP2K1 | |
| SCHEMBL17374996 | 0.83 | MAP2K2 (0.42) | MAP2K1 | |
| SCHEMBL9534684 | 0.83 | PTGS2 (0.54) | SLC22A12PARP14MAP2K1 | |
| SCHEMBL4593012 | 0.81 | TNIK (0.48) | SLC22A12PARP14PGRNR3C1 | |
| SCHEMBL6389949 | 0.80 | SLC22A12 (0.47) | SLC22A12PARP14PGRNR3C1 | |
| SCHEMBL4641810 | 0.80 | SLC22A12 (0.54) | SLC22A12PARP14PGRNR3C1 | |
| SCHEMBL9340013 | 0.78 | PARP14 (0.48) | SLC22A12PARP14PGRNR3C1 | |
| SCHEMBL9655254 | 0.78 | PTGS2 (0.58) | SLC22A12 | |
| SCHEMBL12060800 | 0.78 | SLC22A12 (0.45) | SLC22A12PARP14PGRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796328-B2 | TRPV1 antagonists | ABBVIE INC. | 2014-08-05 | — | — | US | disclosed |
| US-20130345255-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. | 2013-12-26 | — | — | US | disclosed |
| US-7994167-B2 | Pentafluorosulphanyl-substituted compound and its use for producing medicaments | GRUENENTHAL GMBH (DE) | 2011-08-09 | — | — | US | disclosed |
| US-7960584-B2 | 3-(4-t-butyl-phenyl)-N-(4-methanesulfonylamino-benzyl)-2-methyl-acrylamide; pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane | AMOREPACIFIC CORPORATION (KR) | 2011-06-14 | — | — | US | disclosed |
| US-20090137594-A1 | Pentafluorosulphanyl-Substituted Compound And Its Use For Producing Medicaments | GRUENENTHAL GMGH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-20080234383-A1 | Novel Compounds, Isomer Thereof, or Pharmaceutically Acceptable Salts Thereof as Vanilloid Receptor Antagonist; and Pharmaceutical Compositions Containing the Same | AMOREPACIFIC CORPORATION (KR) | 2008-09-25 | — | — | US | disclosed |
| US-20080227995-A1 | Process of Sulfonating 4-Aminobenzonitriles | SCHWARZ PHARMA AG (DE) | 2008-09-18 | — | — | US | disclosed |
| US-20080227995-A1 | Process of Sulfonating 4-Aminobenzonitriles | SCHWARZ PHARMA AG (DE) | 2008-09-18 | — | — | US | disclosed |
| US-20080227995-A1 | Process of Sulfonating 4-Aminobenzonitriles | SCHWARZ PHARMA AG (DE) | 2008-09-18 | — | — | US | disclosed |
| EP-1910280-A2 | PROCESS OF SULFONATING 4-AMINOBENZONITRILES | SCHWARZ PHARMA AG (DE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1861358-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007009798-A2 | PROCESS OF SULFONATING 4-AMINOBENZONITRILES | SCHWARZ PHARMA AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009798-A2 | PROCESS OF SULFONATING 4-AMINOBENZONITRILES | SCHWARZ PHARMA AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006101321-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234383-A1 | Novel Compounds, Isomer Thereof, or Pharmaceutically Acceptable Salts Thereof as Vanilloid Receptor Antagonist; and Pharmaceutical Compositions Containing the Same | TRPV1, TRPA1, TRPV5 | SLC22A12 1031/4885PARP14 2975/4885PGR 1469/4885 |
| US-20080227995-A1 | Process of Sulfonating 4-Aminobenzonitriles | STS, ARSA, CYP2S1 | SLC22A12 2305/4885PARP14 2413/4885PGR 4857/4885 |
| US-20090137594-A1 | Pentafluorosulphanyl-Substituted Compound And Its Use For Producing Medicaments | FIBP, PFAS, FPR3 | SLC22A12 2925/4885PARP14 1640/4885PGR 4318/4885 |
| US-20130345255-A1 | TRPV1 ANTAGONISTS | TRPV1, NPY1R, OPRL1 | SLC22A12 1666/4885PARP14 1859/4885PGR 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.